New York is currently home to 4475 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
Recruiting
Background: Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States. Researchers want to learn more about liver cancer to help them design better treatments. Objective: To better understand liver cancer. Eligibility: People ages 18 and older who have liver cancer and had or are planning to have immune therapy Design: Participants will be screened with a review of their med... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
Recruiting
This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/20/2025
Locations: Northwell Health, New Hyde Park, New York
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Phase I Study of Fractionated Stereotactic Radiation Therapy
Recruiting
There is a lack of prospective trial data and consensus guidelines describing the use of Fractionated Stereotactic Radiation Therapy (FSRT) in the treatment of brain metastases. There has been no prospective dose escalation study performed to date to determine the maximum tolerated dose (MTD) in patients treated with FSRT. Prescription doses in the series described above ranged from 18 Gy to 42 Gy, delivered in 3 to 12 fractions. The results of this study will be used to plan future Phase II/III... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Brain Metastases
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
Recruiting
The purpose of this study is to find out the effectiveness of pembrolizumab in combination with BCG as a first line therapy for participants with high grade T1 bladder cancer who are at "high risk" for BCG alone to be ineffective and are seeking an alternative treatment option to radical cystectomy. There is biologic rationale for combining pembrolizumab and BCG as two distinct immunotherapies with possible additive or synergistic activity in urothelial cancer. The combination of pembrolizumab w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Memorial Sloan Kettering Commack (All protocol activities), Commack, New York
Conditions: Bladder Cancer
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Recruiting
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: North Shore University Hospital, Manhasset, New York
Conditions: Mitral Valve Regurgitation
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Recruiting
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Northwell Health - Center for Liver Diseases, Manhasset, New York
Conditions: Hepatocellular Cancer
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
05/20/2025
Locations: The Children's Hospital at Montefiore, Division of Pediatric GI, Bronx, New York
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Recruiting
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical allogeneic stem cell transplantation with CD34 enrichment and T-cell addback. This patient population historically has a risk of developing sinusoidal obstructive syndrome (SOS) and Defibrotide has demonstrated efficacy in treatment of SOS. The Funding Source is FDA OOPD... Read More
Gender:
ALL
Ages:
Between 6 months and 34 years
Trial Updated:
05/20/2025
Locations: New York Medical College, Valhalla, New York
Conditions: Sickle Cell Disease
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Recruiting
The overall objectives of this BETRNet Research Center (RC) are: 1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biological understanding of key observations made by our clinical researchers; 3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Barrett's Esophagus, Esophageal Neoplasm
Comparing Two Eccentric Protocols on Muscle Damage
Recruiting
The purpose of this study will be to test whether a new way of weight training is more effective than typical weight training. The investigators expect that this new way will cause more exercise-induced muscle damage, which helps people build bigger muscles. Another purpose of this study will be to explore perceptions of how muscle soreness impacts participant activities of daily living.
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
05/19/2025
Locations: NYIT, Old Westbury, New York
Conditions: Eccentric Hypertrophy, Muscle Damage
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Recruiting
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME). In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Liverpool, NY, Liverpool, New York
Conditions: Diabetic Macular Edema (DME)
Quantitative Xylazine Measurement in ED
Recruiting
Quantitative Xylazine Measurement Among Non-Fatal Opioid Overdose (OD) Patients in the Emergency Department (ED)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: NYC Health + Hospitals/Elmhurst, Elmhurst, New York
Conditions: Opioid Overdose, Substance Use Disorders